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Abstract
Background Polypharmacy is associated with an increased risk of adverse drug events, inappropriate prescribing and medi-
cation errors. People with bronchiectasis have frequent pulmonary exacerbations that require antibiotic therapy. Objective 
This study aimed to measure polypharmacy and medication regimen complexity in bronchiectasis patients and to explore 
associations between these factors and oral and intravenous (IV) antibiotic use for suspected pulmonary exacerbations. Set-
ting Patients were sampled from the Regional Bronchiectasis Clinic at the Belfast Health and Social Care Trust, Northern 
Ireland. Method Data on medicines were collected from patients’ records and used to measure polypharmacy using three 
thresholds (≥ 4, ≥ 10, and ≥ 15 medicines’). Medication regimen complexity was calculated using the medication regimen 
complexity index (MRCI). Data analysis investigated differences in outcomes across polypharmacy thresholds and correla-
tions with MRCI. Main outcome measure Primary outcomes were prescriptions for oral antibiotics and IV antibiotics, in 
the past 6 months and 2 years, respectively. Results Over three-quarters of the sample (N = 95) were prescribed ≥ 4 medi-
cines (n = 74; 77.9%), 31 patients were prescribed ≥ 10 medicines (33.0%), and 12 patients (12.8%) were prescribed ≥ 15 
medicines. The median MRCI was 26. Patients prescribed ≥ 10 medicines were over three times more likely to have had 
an IV antibiotic in the past 2 years (adjusted odd ratio 3.44, 95% confidence intervals 1.15–10.31). Conclusion There were 
significant differences in all outcomes across the ‘≥ 10 medicines’ threshold. MRCI was positively correlated with oral and 
IV antibiotic usage. These findings also suggest a possible link between polypharmacy and medicines regimen complexity, 
and poorer outcomes.
Keywords Antibiotics · Bronchiectasis · Ireland · Medication regimen complexity · Polypharmacy · Pulmonary 
exacerbations · Treatment burden · United Kingdom
Impacts on practice
• Health professionals caring for people with bronchiec-
tasis should be vigilant to the potential impact of polyp-
harmacy and complex medication regimens on clinical 
outcomes, such as pulmonary exacerbations, and take 
appropriate action to optimise treatment where possible.
• Regular medication review by a pharmacist in people 
with bronchiectasis who are experiencing frequent pul-
monary exacerbations may offer a low-risk solution to a 
potentially high-risk problem, and could be incorporated 
into routine practice without delay.
• The prescription of 10 or more medicines may be an 
appropriate threshold to prompt medication review in 
patients with bronchiectasis.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1109 6-018-0681-1) contains 
supplementary material, which is available to authorized users.
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Introduction
Polypharmacy is the concurrent use of multiple prescribed 
medicines in one individual [1]. It is associated with an 
increased risk of adverse drug events, inappropriate pre-
scribing and medication errors [1, 2]. Polypharmacy 
contributes to increased treatment burden—defined as 
a ‘dynamic multidimensional concept that is comprised 
of both subjective and objective elements’—of which 
poor adherence and suboptimal health outcomes are 
likely consequences [3]. There is no consensus as to how 
many medicines constitute polypharmacy; most sources 
cite a minimum of four medicines [4]. The prescription 
of more than 10 medicines has been described using the 
term ‘excessive polypharmacy’ [5]. Guidance from the 
National Institute for Health and Care Excellence (NICE) 
uses polypharmacy as a marker for identifying people with 
multimorbidity [6]. The guidance provides two distinct 
thresholds (10 or more, and 15 or more medicines) for 
when multimorbidity is likely to become problematic and 
in need of intervention [7].
The complexity of treatment is also believed to con-
tribute to the treatment burden imposed on patients [3]. 
Medication regimen complexity (MRC) is the presence 
and combination of different dosage forms and frequen-
cies in a person’s medication regimen. The most frequently 
used validated tool for measuring complexity is the Medi-
cation Regimen Complexity Index (MRCI) [4], which uses 
three ‘facets of complexity’ to quantify complexity [8]. 
The MRCI has been proposed as a risk assessment tool for 
identifying patients who would be suitable for medication 
review and intervention [9, 10].
People with bronchiectasis have frequent pulmo-
nary exacerbations, which are treated acutely with short 
courses (14 days) of antibiotics [11]. Oral preparations are 
typically used first line, with intravenous (IV) antibiot-
ics reserved for patients who fail to respond to oral treat-
ment, exacerbations caused by resistant microorganisms 
and severe exacerbations [11].
To the best of the authors’ knowledge, the prescribing of 
polypharmacy and complexity of medication regimens in 
patients with bronchiectasis has not been investigated before.
Aim of the study
This study aimed to determine the extent of polypharmacy 
and MRC in patients with bronchiectasis and to explore 
associations between these two factors and the prescription 
of oral and IV antibiotics for the treatment of suspected 
pulmonary exacerbations.
Ethics approval
This study was reviewed by the Quality and Audit Depart-
ment at the Belfast Health and Social Care Trust (BHSCT) 
on 27th July 2016, judged to be an audit and approved as 
such.
Method
Study design
This study was a retrospective observational study of the 
number and complexity of medicines prescribed, and anti-
biotic use (oral and IV), in a sample of patients with bron-
chiectasis. Consecutive sampling was used to select a target 
sample size of approximately 100 patients. Patients aged 
18 years or older and who had been radiologically diagnosed 
with non-cystic fibrosis bronchiectasis. Patients were sam-
pled in the order they had attended the Regional Bronchiec-
tasis Clinic at BHSCT, Northern Ireland.
Data collection
All data were collected by a researcher (MS) from patients’ 
electronic care records (ECRs) between 28th July 2016 and 
4th October 2016, as close to the patients’ clinic visits as 
possible. Demographic and disease related data included 
age, gender, number of comorbidities, forced expiratory 
volume in 1 s  (FEV1; percentage predicted) and latest spu-
tum microbiology. The Charlson Comorbidity Index (CCI), a 
clinical risk assessment tool, was used to quantify the burden 
of certain comorbidities and predict mortality, with a higher 
score indicating a greater burden and greater risk of mortal-
ity [12]. A newer, validated bronchiectasis-specific comor-
bidity index, the Bronchiectasis Aetiology and Comorbidity 
Index (BACI) was also calculated [13].
Data on medicines regularly prescribed for patients by 
their general practitioner (GP), including drug name, pre-
scribed dose and frequency of administration, quantity pre-
scribed and date the drug was first and last issued, were 
collected. This information was used to compile a list of all 
medicines each patient was prescribed at the time of their 
clinic visit. Different strengths and formulations of the same 
medicine were counted separately.
The total number of prescribed medicines was determined 
by absolute count. Patients’ medication counts were used to 
identify whether or not three thresholds for polypharmacy 
(‘≥ 4 medicines’, ‘≥ 10 medicines’’ and ‘≥ 15 medicines’) 
had been exceeded.
MRCI scores were calculated using information collected 
about prescribed medicines [8]. The MRCI consists of 65 
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items divided into three sections: ‘Dosage forms’, ‘Dos-
age frequencies’ and ‘Additional instructions’. Each item 
is weighted according to the relative degree of complex-
ity it contributes to the regimen [8]. Scores begin at 0 and 
because patients may be on any number of medicines, there 
is no maximum MRCI score. There are no widely recognised 
thresholds that represent particularly low, medium or high 
MRCI scores.
The primary outcomes of interest were oral antibi-
otic usage for suspected pulmonary exacerbations in the 
6 months prior to clinic attendance, and IV antibiotic usage 
in secondary care in the 2 years prior to clinic attendance. 
Secondary outcomes included the total number of days’ 
treatment with IV antibiotics and admissions to hospital 
(all-cause and bronchiectasis-related) in the 2 years prior 
to clinic visit.
Medications prescribed for patients on an acute basis by 
GPs, including short courses of antibiotics, are recorded in 
patients’ ECRs. The following information regarding oral 
antibiotics prescribed for patients was recorded: issue date, 
antibiotic name and dose, frequency of administration, and 
duration prescribed (days). Indications for antibiotics are 
rarely specified on prescriptions issued in primary care. Oral 
antibiotic use for a pulmonary exacerbation was suspected if 
one or more of the following factors were present: the patient 
was prescribed an appropriate antibiotic (e.g., doxycycline, 
amoxicillin, co-amoxiclav, clarithromycin) for 14-days, and/
or a sputum sample was collected and tested within a week 
of the prescription being issued [11]. Clinic notes were also 
consulted to check if the patient had reported any exacerba-
tions since their last visit. In cases of ambiguity, the patients’ 
consultant physician provided clinical judgment of whether, 
or not, an antibiotic had been prescribed for a suspected 
pulmonary exacerbation. Only medicines prescribed in the 
past 6-months are available to view at the time of data col-
lection, hence the 6-months time period for documenting 
oral antibiotic use.
IV antibiotic use was determined using data from 
patients’ discharge summary letters, which are available to 
view on the ECR and records extend back several years. 
Data regarding all IV antibiotics (date prescribed, name of 
antibiotic and duration of therapy) prescribed for patients 
for the treatment of an acute exacerbation of bronchiectasis 
and all hospitalisations in the past 2 years were collected. 
There was less ambiguity regarding the indication of IV anti-
biotics during hospital admissions because the indication 
of prescribed treatment during a hospital stay is routinely 
documented. IV antibiotic use and secondary outcomes were 
investigated over a longer period than oral antibiotic use to 
mitigate for seasonal variations in exacerbation rates.
A power calculation, based on a comparison of the 
mean number of times an oral antibiotic was prescribed 
for a suspected exacerbation in the preceding 6 months 
between patients who were prescribed 10 or more medi-
cines and those who were prescribed less than 10 medicines, 
was performed prior to data collection. McCullough et al. 
[14] suggested a difference of two exacerbations within a 
12-month period was importance clinically important dif-
ference. Assuming the standard deviation of exacerbations 
in 6 months was 1 (based upon findings from McCullough 
et al. [14]), with 100 patients, the power to detect a differ-
ence of one exacerbation within 6 months as significant at 
the 5% level was over 80%.
Data analysis
All data were entered into IBM SPSS (Version 23). The 
Mann–Whitney U test was used to investigate if there was 
a significant difference in the primary and secondary out-
comes of patients below and above the three thresholds for 
polypharmacy. Effect sizes (r) were calculated using the cal-
culation ‘r = z/square root of N, where z is the standardized 
test statistic and N = number of cases’ [15].
Correlations between MRCI and the primary and second-
ary outcomes were investigated using Spearman rank-order 
correlation coefficient (Spearman’s correlation, rs). Correla-
tions were considered strong/large if r = 0.5–1.0; moderate/
medium if r = 0.3–0.5; weak/small if r = 0.1–0.3 [15].
To further investigate the association between polyphar-
macy and IV antibiotic use, patients were grouped into those 
who had had a course of IV antibiotics for the treatment of 
an exacerbation in the past 2 years and those who had not 
(status: did not receive IV antibiotics = 0, did receive anti-
biotics = 1). Chi square (χ2) tests were conducted to deter-
mine whether, or not, there was a difference in receipt of an 
IV antibiotic in the past 2 years between people who were 
above and below each of the three polypharmacy thresholds. 
Where significant differences were identified, unadjusted 
odds ratios were calculated. Other demographic and disease-
related factors (age, gender, testing positive for P. aerugi-
nosa or H. influenzae), and comorbidities may contribute 
to a higher exacerbation rate. Logistic regression was then 
used to adjust odds ratios for any other factors that could 
have potentially influenced the need for IV antibiotic use. 
The significance level was set at p ≤ 0.05 for all statistical 
tests. The associations between oral antibiotic use and poly-
pharmacy were not investigated in this way because there 
was less certainty over the indication of oral antibiotic use.
Results
Ninety-five patients were included in the study. Demo-
graphic and disease-related data of the sample population 
are outlined in Table 1.
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Medication count per person ranged from 0 to 24 medi-
cines. There was a median of 8 medicines per person and 
the interquartile range (IQR) was 7. Over three-quarters of 
patients in the sample were prescribed four or more medi-
cines (n = 74; 77.9%), a third of patients were prescribed 10 
or more medicines (n = 31; 33.0%), and 12 patients (12.8%) 
were prescribed 15 or more medicines. Total MRCI scores 
ranged from 0 to 68.5 and the median MRCI score was 26 
(IQR 13.3–36.1).
Patients who were above the ‘≥ 4 medicines’ polyp-
harmacy threshold had significantly more courses of oral 
antibiotics prescribed by their GP for a presumed pulmo-
nary exacerbation in the past 6 months (effect size, r = 0.36; 
p < 0.001) and more admissions to hospital (all-cause) in the 
past 2 years (r = 0.32; p = 0.002) compared with patients who 
were below the threshold. There was no significant differ-
ence in IV antibiotic usage, duration of IV antibiotic therapy 
or admissions to hospital (bronchiectasis-related) across this 
threshold.
There were significant differences in all measured out-
comes across the ‘≥ 10 medicines’ polypharmacy threshold. 
Effect sizes varied from weak to moderate, with the strongest 
effect size being for the number of admissions to hospital 
(all-cause) in the past 2 years (r = 0.4; p < 0.001).
At the ‘≥ 15 medicines’ threshold, the only significant 
difference was in the number of admissions to hospital 
(all-cause; r = 0.26; p = 0.011). Tables detailing computed 
U-statistics, effect sizes and p-values are provided in the 
electronic supplementary material.
There were significant positive correlations found 
between MRCI and all health outcomes. The strongest corre-
lation was with the number of admissions to hospital for any 
reason in the past 2 years (rs= 0.413; p < 0.001), followed 
by the number of exacerbations managed with oral antibiot-
ics in the past 6 months (rs= 0.318; p = 0.003). Correlation 
coefficients between MRCI and outcomes are outlined in the 
electronic supplementary material.
A significant difference was detected across the ‘≥ 10 
medicines’ threshold (χ2= 4.912, p = 0.048) in the num-
ber of patients who had received an IV antibiotic in the 
past 2 years. The unadjusted odds ratio for the relation-
ship was calculated by cross-tabulation to be 2.83 (95% CI 
1.11–7.24).
Age, exceeding the ‘≥ 10 medicines’ polypharmacy 
threshold and P. aeruginosa status were included in the final 
logistic regression model (Table 2). Although included in 
the final model, age had no effect on whether or not patients 
had received IV antibiotics in the past 2 years (odds ratio 
0.95, 95% CI 0.92–0.99). Exceeding the ‘≥ 10 medicines’ 
polypharmacy threshold significantly increased the likeli-
hood that an IV antibiotic had been prescribed in the past 
Table 1  Demographic and disease-related data of sample population
SD standard deviation, IQR interquartile range
*Mean  FEV1 missing for 42 patients
Characteristic Result
Gender n (%)
 Female 65 (68.4)
 Male 30 (31.6)
Age
 Mean, y (SD) 62.6 (14.8)
FEV1 % predicted
 Mean (SD)* 80.9 (35.8)
Sputum microbiology n (%)
 Not recorded in past 6 months 30 (31.6)
 Pseudomonas aeruginosa 17 (17.9)
 Haemophilus influenzae 13 (13.7)
 Streptococcus pneumonia, 1 (1.1)
 Staphylococcus aureus 0 (0)
 Moraxella catarrhalis 1 (1.1)
 Escherichia coli 1 (1.1)
 No significant growth 32 (33.7)
Number of comorbidities n (%)
 0 19 (20.0)
 1 25 (26.3)
 2 24 (25.3)
 3 14 (14.7)
 4 10 (10.5)
 5 3 (3.2)
 Median (IQR) 2 (2)
Charlson comorbidity index (CCI) n (%)
 0 52 (54.7)
 1 25 (26.3)
 2 11 (11.6)
 3 3 (3.2)
 4 3 (3.2)
 5 1 (1.1)
 Median (IQR) 0 (1)
Bronchiectasis aetiology and comorbidity index (BACI) n (%)
 Low risk (0) 55 (57.9)
 Intermediate risk (1–5) 30 (31.6)
 High risk (6 or more) 10 (10.5)
 Median (IQR) 0 (5)
Table 2  Adjusted odds ratios for factors found to significantly influ-
ence receipt of an intravenous antibiotic in the past 2 years, in a sam-
ple of patients with bronchiectasis
Factor Odds ratio 95% 
confidence 
interval
Significance (p)
≥ 10 medicines 3.44 1.15–10.31 0.027
Age 0.95 0.92–0.99 0.010
P. aeruginosa positive 6.45 1.88–22.19 0.003
International Journal of Clinical Pharmacy 
1 3
2 years when adjusted for age and P. aeruginosa status, com-
pared with being prescribed less than 10 medicines (adjusted 
odds ratio 3.44, 95% CI 1.15–10.31).
Discussion
In this study of polypharmacy and MRC in patients with 
bronchiectasis, the prevalence of polypharmacy as defined 
by its lowest cited threshold was high. There was almost 
a four-fold difference in prevalence of polypharmacy in 
patients with bronchiectasis compared with the general pop-
ulation. The prevalence of polypharmacy, as defined using 
the ‘≥ 4 medicines’ threshold, amongst middle-aged peo-
ple aged 45–65 years living in NI is 20.3% [2]. In an older 
cohort (over 70 years old) of patients living in UK, 23% of 
patients were prescribed four or more medicines [16]. The 
number and severity of comorbidities (as investigated using 
the CCI) were similar to the study presented in this paper 
[16].
MRCI scores ranged from 0 to 68.5, indicating that com-
plexity varied substantially within the sample. The median 
MRCI score was 26, which was high in comparison to other 
MRC studies [10, 17, 18] and comparable to the findings of 
Negewo and colleagues who investigated MRCI in patients 
with COPD (median MRCI 24; IQR 18.5–31) [19]. MRCI 
is likely to be higher in people with respiratory disease due 
to the frequent use of different inhalation devices in these 
populations. Such formulations are heavily weighted in the 
MRCI [8]. Comparison of MRCI scores with other chronic 
respiratory diseases would help to inform the significance 
of the high MRCI determined in this study.
The high prevalence of polypharmacy and MRC pre-
scribed for the sample population is concerning. These 
findings indicate that a considerable number of patients 
are at an increased risk of adverse drug events, potentially 
inappropriate prescribing and medication errors, which have 
been shown to be associated with polypharmacy [1, 2]. The 
findings of this study suggest that the prescription of 10 
or more medicines is an appropriate threshold to prompt a 
medication review in patients with bronchiectasis. The role 
of pharmacists in medication reviews is well established and 
addition of regular pharmacy support to the bronchiectasis 
service may prove to be beneficial to patients [20].
This study also sought to investigate differences in oral 
and IV antibiotics use for across three different thresholds 
used to define polypharmacy. The ‘≥ 10 medicines’ thresh-
old emerged as being the level at which, when exceeded, 
polypharmacy appeared more problematic for the study sam-
ple, based on the outcomes selected. There was a significant 
difference in all primary and secondary outcomes evaluated 
between patients below the ‘≥ 10 medicines’ threshold 
and those who exceeded it. That is, patients exceeding this 
threshold were prescribed oral and IV antibiotics more fre-
quently, were admitted to hospital more often and received 
more IV antibiotics. Furthermore, patients who exceeded 
this threshold were found to be 3.44 times more likely to 
have required an IV antibiotic in the past 2 years when 
adjusted for P. aeruginosa infection.
Strengths and limitations
This was a retrospective study and as such, precise measure-
ment of pulmonary exacerbations was not possible. Instead, 
this study investigated antibiotic use for suspected pulmo-
nary exacerbations and made assumptions with regards to 
the indication of oral antibiotics prescribed in primary care. 
These limitations, and those listed below, restrict the extent 
to which firm conclusions on the impact of treatment burden 
may be having on people with bronchiectasis. Although the 
findings of this study do not demonstrate causation, higher 
rates of antibiotic use, whether bronchiectasis-related or not, 
were observed in those patients who were prescribed poly-
pharmacy and complex medication regimens. Conversely, 
antibiotics may have led to polypharmacy through treatment 
to combat adverse effects of those antibiotics. We did not 
consider appropriateness of polypharmacy in this study, and 
this is worthy of further exploration as patients with bron-
chiectasis are likely to be receiving multiple medications.
A sample size of 100 was calculated as having suffi-
cient power (over 80%) in an independent samples t test 
that aimed to detect a difference of one exacerbation within 
6 months as significant at the 5% level. The study achieved 
an adequate sample size of within 5% of the target (N = 95). 
Although consecutive sampling restricts the generalisability 
of the study, this method of sampling provided a useful illus-
tration of the patient population attending the bronchiectasis 
clinic during the data collection period [21]. Furthermore, 
the demographics (age, gender, aetiology, sputum microbiol-
ogy) of the sample population were found to be representa-
tive of the wider bronchiectasis population who are under 
specialist care [22, 23] The use of referenced thresholds for 
polypharmacy and validated tools (CCI, BACI and MRCI) 
enhances the validity of this study.
Due to the retrospective design of this study, many 
assumptions regarding medication use, both for regular 
medications and acute use of antibiotics were made. Non-
adherence to medications, a known consequence of high 
treatment burden [3], was not considered. There were limi-
tations to the information available on ECRs regarding the 
prescription of oral antibiotics by GPs. Only oral antibiotics 
that had been prescribed for patients in the past 6 months 
were available to view on the ECR. Furthermore, regular 
medicines prescribed by non-respiratory hospital specialists 
may have been missed during data collection. As such, the 
extent of polypharmacy and complexity of the medication 
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regimens may have been underestimated. An accuracy check 
on data extraction was not performed due to restrictions in 
time and access to patient data. Findings may also have been 
affected by the time of year data were collected. Patients 
tend to exacerbate more frequently over winter than sum-
mer; therefore, a different pattern of oral antibiotic use may 
be observed if the study was repeated at a different time of 
year. Furthermore, we did not consider the impact of co-
morbidities and the social environment on our findings.
Conclusion
In conclusion, there is a high prevalence of polypharmacy 
and MRC in patients with bronchiectasis. Polypharmacy was 
associated with poorer outcomes when more than 10 medi-
cines were prescribed, with patients exceeding this threshold 
being prescribed oral and IV antibiotics more frequently, 
being admitted to hospital more often and receiving more 
IV antibiotics. MRC was also associated with increased anti-
biotic use and more frequent admissions to hospital. The 
routine management of patients with bronchiectasis should 
consider the burden of treatment imposed on patients when 
reviewing outcomes.
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